SSY Group Ltd banner
S

SSY Group Ltd
HKEX:2005

Watchlist Manager
SSY Group Ltd
HKEX:2005
Watchlist
Price: 2.39 HKD Market Closed
Market Cap: HK$6.9B

SSY Group Ltd
Accrued Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

SSY Group Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
S
SSY Group Ltd
HKEX:2005
Accrued Liabilities
HK$483.2m
CAGR 3-Years
-3%
CAGR 5-Years
1%
CAGR 10-Years
1%
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
Accrued Liabilities
$661.1k
CAGR 3-Years
6%
CAGR 5-Years
46%
CAGR 10-Years
N/A
G
Grand Pharmaceutical Group Ltd
HKEX:512
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sino Biopharmaceutical Ltd
HKEX:1177
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Accrued Liabilities
HK$57.8m
CAGR 3-Years
-76%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Accrued Liabilities
$190.2m
CAGR 3-Years
-8%
CAGR 5-Years
11%
CAGR 10-Years
N/A
No Stocks Found

SSY Group Ltd
Glance View

Market Cap
6.9B HKD
Industry
Pharmaceuticals

SSY Group Ltd. stands out as a significant player in the Chinese pharmaceutical industry, seamlessly interweaving its intricate supply chain operations with its robust manufacturing capabilities. Founded in 1994, the company has its roots in the scenic Hebei Province and has evolved into a powerful force in the realm of injectable pharmaceuticals and oral solutions. The organization primarily operates through its core segment—manufacturing and distributing intravenous infusion solutions. By leveraging cutting-edge technology and adhering to stringent quality standards, SSY Group has managed to capture a sizable share of the domestic market, ensuring a steady stream of revenue. The firm's prowess isn't limited to its pharmaceutical expertise. SSY Group's growth strategy involves a careful blend of organic expansion and strategic acquisitions, which enables it to broaden its product categories and penetrate new regional markets. By offering a wide variety of products ranging from antibiotics to anti-infection drugs, the company adeptly meets diverse healthcare needs while simultaneously driving profitability. Additionally, SSY Group bolsters its financial performance through its involvement in both research and development. By dedicating resources toward innovation, it aspires to maintain its competitive edge, producing high-value products that facilitate sustainable long-term growth. Thus, SSY Group's tightly-knit approach to blending manufacturing excellence with strategic growth initiatives paints a picture of a company adeptly navigating the challenges and opportunities of the healthcare sector.

Intrinsic Value
3.49 HKD
Undervaluation 31%
Intrinsic Value
Price HK$2.39
S

See Also

What is SSY Group Ltd's Accrued Liabilities?
Accrued Liabilities
483.2m HKD

Based on the financial report for Dec 31, 2025, SSY Group Ltd's Accrued Liabilities amounts to 483.2m HKD.

What is SSY Group Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
1%

Over the last year, the Accrued Liabilities growth was -13%. The average annual Accrued Liabilities growth rates for SSY Group Ltd have been -3% over the past three years , 1% over the past five years , and 1% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett